Every year, multidrug-resistant tuberculosis sickens more than half a million people and kills more than 200,000 around the world.
Although drugs are available that can treat and cure MDR-TB, currently only about 10 percent of people with MDR-TB get treatment that cures them and prevents further transmission of the infectious airborne disease. But in the glow of a special United Nations general assembly meeting on tuberculosis in September, endTB, a global research project that is improving treatment regimens for patients with MDR-TB, received a boost when Unitaid announced that it is intensifying its commitment to fighting TB with a $21 million investment in the project.
“This landmark extension ensures that people around the world who suffer from multidrug-resistant TB will have a chance to get an all-oral, shortened regimen, which would be prescribed based on the best possible evidence,” said Carole Mitnick, associate professor of global health and social medicine at Harvard Medical School, senior researcher at Partners In Health and co-principal investigator of endTB’s clinical trials.
The extended endTB project works to identify regimens that can be confidently and easily delivered to 100 percent of affected patients, Mitnick said. The ultimate goal of the project is to provide countries and funding agencies, such as the Global Fund, with effective regimens that can be introduced on a massive scale to tackle MDR-TB.
Led by PIH, in partnership with Médecins Sans Frontières, Interactive Research & Development, HMS, the Institute of Tropical Medicine (Antwerp), and Epicentre, endTB has been piloting two new medicines, bedaquiline and delamanid, in 17 countries. The pilot program aims to make treatment for MDR-TB shorter, simpler, more effective, and with fewer side effects.